NCT00660101 - Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions

Adenocarcinoma of the Ovary

Interventions

BIOLOGICAL

OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine

OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months

Trial Locations (3)

19124

Cancer Treatment Centers of America (ERMC), Philadelphia

60099

Cancer Treatment Centers of America (CTCA-Midwestern), Zion

74133

Cancer Treatment Centers of America (CTCA-Southwestern), Tulsa